Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
SER Serina Therapeutics Inc.
- Stocks
- Healthcare
- NYSEAMERICAN: SER
Price (delayed)
$5.7453
Market cap
$57.27M
P/E Ratio
574.53
Dividend/share
N/A
EPS
$0.01
Enterprise value
$53.23M
agex therapeutics, inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the united states. the company's lead cell-based therapeutic
Highlights
The quick ratio has surged by 187% year-on-year and by 17% since the previous quarter
The equity has surged by 165% since the previous quarter and by 139% year-on-year
Serina Therapeutics's gross profit has shrunk by 98% YoY and by 9% QoQ
The revenue has dropped by 98% year-on-year and by 9% since the previous quarter
Key stats
What are the main financial stats of SER
Market
Valuations
Earnings
Shares outstanding
9.97M
Market cap
$57.27M
Enterprise value
$53.23M
Price to earnings (P/E)
574.53
Price to book (P/B)
33.55
Price to sales (P/S)
1,099.04
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,043.64
Revenue
$51,000
Gross profit
$51,000
Operating income
-$20.59M
Net income
-$939,000
EBIT
-$664,000
EBITDA
-$235,000
Free cash flow
-$19.89M
Per share
Balance sheet
Liquidity
EPS
$0.01
EPS diluted
-$0.12
Free cash flow per share
-$2.04
Book value per share
$0.17
Revenue per share
$0.01
TBVPS
$0.69
Total assets
$6.73M
Total liabilities
$5.17M
Debt
$227,000
Equity
$1.7M
Working capital
$3.4M
Debt to equity
0.13
Current ratio
2.45
Quick ratio
1.81
Net debt/EBITDA
17.19
Margins
Efficiency
Dividend
EBITDA margin
-460.8%
Gross margin
100%
Net margin
-1,841.2%
Operating margin
-40,362.7%
Return on assets
-11.9%
Return on equity
N/A
Return on invested capital
-43.8%
Return on capital employed
-15.2%
Return on sales
-1,302%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SER stock price
How has the Serina Therapeutics stock price performed over time
Intraday
-0.08%
1 week
8.2%
1 month
8.61%
1 year
-37%
YTD
14.68%
QTD
1.33%
Financial performance
How have Serina Therapeutics's revenue and profit performed over time
Revenue
$51,000
Gross profit
$51,000
Operating income
-$20.59M
Net income
-$939,000
Gross margin
100%
Net margin
-1,841.2%
Serina Therapeutics's gross profit has shrunk by 98% YoY and by 9% QoQ
The revenue has dropped by 98% year-on-year and by 9% since the previous quarter
The net income has surged by 92% year-on-year and by 92% since the previous quarter
The company's net margin has surged by 91% QoQ
Price vs fundamentals
How does SER's price correlate with its fundamentals
Growth
What is Serina Therapeutics's growth rate over time
Valuation
What is Serina Therapeutics stock price valuation
P/E
574.53
P/B
33.55
P/S
1,099.04
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,043.64
The company's EPS has surged by 101% QoQ and by 100% YoY
The equity has surged by 165% since the previous quarter and by 139% year-on-year
The price to sales (P/S) is 146% higher than the last 4 quarters average of 446.9
The revenue has dropped by 98% year-on-year and by 9% since the previous quarter
Efficiency
How efficient is Serina Therapeutics business performance
The ROIC has soared by 96% QoQ and by 68% YoY
The company's return on sales has surged by 93% QoQ
Serina Therapeutics's ROA has soared by 90% from the previous quarter and by 88% YoY
Dividends
What is SER's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SER.
Financial health
How did Serina Therapeutics financials performed over time
Serina Therapeutics's total assets is 30% higher than its total liabilities
The quick ratio has surged by 187% year-on-year and by 17% since the previous quarter
The company's total liabilities has shrunk by 66% YoY and by 17% QoQ
The company's debt is 87% lower than its equity
The equity has surged by 165% since the previous quarter and by 139% year-on-year
The debt to equity has surged by 105% year-on-year but it has dropped by 69% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.